Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands

被引：0
|
作者：
S. W. Quist
A. J. Postma
K. J. Myrén
L. A. de Jong
M. J. Postma
机构：
[1] University Medical Center Groningen (UMCG),Department of Health Sciences
[2] University of Groningen,Department of Economics, Econometrics and Finance
[3] Asc Academics,undefined
[4] Alexion,undefined
[5] AstraZeneca Rare Disease,undefined
[6] University of Groningen,undefined
来源：
The European Journal of Health Economics | 2023年 / 24卷
关键词：
Ravulizumab; Eculizumab; C5-inhibitors; Hemoglobinuria; Paroxysmal; Cost–benefit analysis; Costs and cost analysis; D61; I19;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1455 / 1472
页数：17
相关论文
共 50 条
  • [1] Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
    Quist, S. W.
    Postma, A. J.
    Myren, K. J.
    de Jong, L. A.
    Postma, M. J.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (09): : 1455 - 1472
  • [2] COST-EFFECTIVENESS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN THE NETHERLANDS
    Quist, S.
    Postma, A. J.
    Myren, K. J.
    de Jong, L.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S99 - S99
  • [3] The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting
    Hakimi, Zalmai
    Wilson, Koo
    McAughey, Eoin
    Pochopien, Michal
    Wojciechowski, Piotr
    Toumi, Mondher
    Knight, Chris
    Sarda, Sujata P.
    Patel, Nikita
    Wiseman, Catherine
    de Castro, Nuno Pinto
    Nazir, Jameel
    Kelly, Richard J.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (13) : 969 - 985
  • [4] Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
    Thomas O’Connell
    Marric Buessing
    Scott Johnson
    Lufei Tu
    Simu K. Thomas
    Ioannis Tomazos
    [J]. PharmacoEconomics, 2020, 38 : 981 - 994
  • [5] COST-UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    OConnell, T.
    Buessing, M. G.
    Johnson, S. J.
    Tu, L.
    Tomazos, I
    Thomas, S. K.
    [J]. VALUE IN HEALTH, 2019, 22 : S341 - S341
  • [6] Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
    O'Connell, Thomas
    Buessing, Marric
    Johnson, Scott
    Tu, Lufei
    Thomas, Simu K.
    Tomazos, Ioannis
    [J]. PHARMACOECONOMICS, 2020, 38 (09) : 981 - 994
  • [7] COST-UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    OConnell, T.
    Buessing, M. G.
    Tu, L.
    Tomazos, I
    Thomas, S. K.
    Myren, K. J.
    [J]. VALUE IN HEALTH, 2019, 22 : S870 - S871
  • [8] Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria
    Rho, Hayeong
    Wells, Richard A.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (08): : 257 - 264
  • [9] Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    Lee, Jong Wook
    Kulasekararaj, Austin G.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (03) : 227 - 237
  • [10] Opportunity Cost of Funding Drugs for Rare Diseases: The Cost-Effectiveness of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    Coyle, Doug
    Cheung, Matthew C.
    Evans, Gerald A.
    [J]. MEDICAL DECISION MAKING, 2014, 34 (08) : 1016 - 1029
12345